DE60022525T2 - Ramipril zur vorbeugung von kardiovaskulären vorfällen - Google Patents

Ramipril zur vorbeugung von kardiovaskulären vorfällen Download PDF

Info

Publication number
DE60022525T2
DE60022525T2 DE60022525T DE60022525T DE60022525T2 DE 60022525 T2 DE60022525 T2 DE 60022525T2 DE 60022525 T DE60022525 T DE 60022525T DE 60022525 T DE60022525 T DE 60022525T DE 60022525 T2 DE60022525 T2 DE 60022525T2
Authority
DE
Germany
Prior art keywords
inhibitor
renin
pharmaceutically acceptable
acceptable derivative
lowering agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60022525T
Other languages
English (en)
Other versions
DE60022525D1 (de
Inventor
Bernward Schoelkens
Norbert Bender
Badrudin Rangoonwala
Salim Yusuf
Hertzel Gerstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22538761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60022525(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of DE60022525D1 publication Critical patent/DE60022525D1/de
Application granted granted Critical
Publication of DE60022525T2 publication Critical patent/DE60022525T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
DE60022525T 1999-08-30 2000-08-30 Ramipril zur vorbeugung von kardiovaskulären vorfällen Expired - Lifetime DE60022525T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15143699P 1999-08-30 1999-08-30
PCT/EP2000/008461 WO2001015674A2 (en) 1999-08-30 2000-08-30 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Publications (2)

Publication Number Publication Date
DE60022525D1 DE60022525D1 (de) 2005-10-13
DE60022525T2 true DE60022525T2 (de) 2006-06-14

Family

ID=22538761

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60022525T Expired - Lifetime DE60022525T2 (de) 1999-08-30 2000-08-30 Ramipril zur vorbeugung von kardiovaskulären vorfällen

Country Status (31)

Country Link
US (4) US20040087645A1 (de)
EP (1) EP1216038B1 (de)
JP (1) JP4870888B2 (de)
KR (2) KR20120055730A (de)
CN (1) CN1268331C (de)
AT (1) ATE303800T1 (de)
AU (3) AU7649100A (de)
BG (2) BG110003A (de)
BR (1) BR0013704A (de)
CA (1) CA2382549C (de)
CZ (1) CZ300687B6 (de)
DE (1) DE60022525T2 (de)
DK (1) DK1216038T3 (de)
EE (1) EE05670B1 (de)
ES (1) ES2246894T3 (de)
HK (1) HK1048267B (de)
HR (1) HRP20020170A2 (de)
HU (1) HUP0203326A3 (de)
IL (2) IL148127A0 (de)
ME (1) ME00429B (de)
MX (1) MXPA02001694A (de)
NO (1) NO331616B1 (de)
NZ (2) NZ517468A (de)
PL (1) PL353199A1 (de)
RS (1) RS50377B (de)
RU (2) RU2276997C2 (de)
SK (1) SK2692002A3 (de)
TR (1) TR200200515T2 (de)
UA (2) UA77151C2 (de)
WO (1) WO2001015674A2 (de)
ZA (1) ZA200201470B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742506B2 (en) * 1997-10-17 2002-01-03 Eurogene Limited The use of inhibitors of the renin-angiotensin system
CN101011390A (zh) * 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
HUP0203326A3 (en) * 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
PL366419A1 (en) * 2000-08-22 2005-01-24 Boehringer Ingelheim Pharma Bmbh & Co.Kg Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
GB0119460D0 (en) * 2001-08-09 2001-10-03 Ark Therapeutics Ltd The use of inhibitors of the renin-angiotensin system
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2003032965A2 (en) * 2001-10-17 2003-04-24 King Pharmaceuticals Research And Development, Inc Use of ace inhibitors for reducing type 2 diabetes in high risk patients
CA2467095A1 (en) * 2001-11-23 2003-05-30 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
DE10229180A1 (de) * 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
EP1382334A1 (de) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Verwendung von Angiotensin II AT1-Rezeptorblockern, allein oder in Kombination mit Thiazide oder Angiotensin II zur Behandlung von Schlaganfall
US6936639B2 (en) * 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
AU2003274004A1 (en) * 2002-10-16 2004-05-04 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
MXPA05007559A (es) * 2003-01-16 2005-09-21 Boehringer Ingelheim Int Combinacion farmaceutica para la prevencion o la terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales.
KR20120058618A (ko) * 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
WO2005014043A1 (en) * 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
EP1648422A4 (de) 2003-07-28 2007-09-19 Reddys Lab Inc Dr Behandlung und prävention von kardiovaskulären ereignissen
TW200523257A (en) * 2003-09-26 2005-07-16 Novartis Ag Use of organic compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
JP2008503546A (ja) * 2004-06-23 2008-02-07 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング Ｎｅｐ阻害剤、内因性エンドセリン産生系阻害剤およびａｔ１受容体アンタゴニスト阻害剤を含有する医薬組成物
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
CN101098679A (zh) * 2004-11-05 2008-01-02 国王医药研究与发展有限公司 稳定的雷米普利组合物及其制备方法
ATE518526T1 (de) * 2005-01-26 2011-08-15 Lek Pharmaceuticals Neue pharmazeutische zusammensetzung mit candesartan-cilexetil als lipophile kristalline substanz
US20080279942A1 (en) * 2005-06-27 2008-11-13 Takeshi Hamaura Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
WO2007053406A1 (en) * 2005-10-28 2007-05-10 Novartis Ag Combinations of antihypertensive and cholesterol lowering agents
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US20070185065A1 (en) * 2006-02-03 2007-08-09 Vikramjit Chhokar Combination therapy for coronary artery disease
MX2009002091A (es) * 2006-08-28 2009-03-09 Sanofi Aventis Deutschland Metodos para reducir las concentraciones de glucosa.
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
CN101534798B (zh) * 2006-10-30 2012-02-15 韩诺生物制约株式会社 包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物
US8642083B2 (en) 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
US8394845B2 (en) 2006-10-30 2013-03-12 Hanall Biopharma Co., Ltd. Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
NZ596064A (en) * 2009-04-30 2014-03-28 Reddy’S Lab Ltd Dr Fixed dose drug combination formulations
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
EP2509942A2 (de) * 2009-12-07 2012-10-17 Johns Hopkins University Bis-acylierte hydroxylaminderivate
MX2012006349A (es) * 2009-12-07 2012-10-03 Cardioxyl Pharmaceuticals Inc Derivados de n-aciloxisulfonamida y n-hidroxi-n-acilsulfonamida.
CA2790817A1 (en) 2010-02-24 2011-09-01 Sanofi-Aventis Deutschland Gmbh Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
WO2012087090A1 (es) * 2010-12-21 2012-06-28 Laboratorios Silanes S.A. De C.V. Composición estable de agentes reductores de colesterol, antihipertensivos y antiagregantes plaquetarios
BR102012020648A2 (pt) * 2012-08-17 2014-12-09 Hypermarcas S A Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110833620A (zh) * 2018-08-15 2020-02-25 王镕 血管紧张素转化酶抑制剂在防治自身免疫性疾病及相应的并发症中的用途

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (de) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4722810A (en) * 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
DE3413710A1 (de) 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
US5231080A (en) * 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
EP0241201A3 (de) 1986-04-07 1990-05-23 Merck & Co. Inc. Angiotensin-converting-enzyme-Hemmer, nützlich zur Verlängerung des Überlebens von Säugetieren mit hyperämischem Herzversagen
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
DE3704661A1 (de) * 1987-02-14 1988-08-25 Hoechst Ag Annelierte azepinon- und azocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
JPH0657707B2 (ja) 1987-05-25 1994-08-03 吉富製薬株式会社 ピペリジン化合物
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
EP0331014A3 (de) * 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe
US5217958A (en) * 1988-03-03 1993-06-08 E. R. Squibb & Sons, Inc. 1,2-hydroxy phosphonates and derivatives thereof
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3818245A1 (de) * 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
NZ230973A (en) 1988-10-13 1993-03-26 Sandoz Ltd Process for the preparation of 7-substituted, hept-6-enoic and heptanoic acids and selected derivatives and optical isomers
CA2003382A1 (en) * 1988-11-21 1990-05-21 Hollis D. Kleinert Method for treating vascular diseases
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE3926606A1 (de) * 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
US5212165A (en) * 1989-10-23 1993-05-18 E. R. Squibb & Sons, Inc. Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
US5223516A (en) * 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5166143A (en) * 1990-05-31 1992-11-24 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
CA2042526A1 (en) 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
CA2048699A1 (en) 1990-09-04 1992-03-05 Abraham Sudilovsky Method for preventing or treating cerebro-vascular disease employing ceronapril
US5470975A (en) * 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
CA2053340C (en) 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
CA2052014A1 (en) 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5506361A (en) * 1991-05-08 1996-04-09 Theupjohn Company Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
GB9110635D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
US5225401A (en) * 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
AU657793B2 (en) 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
CA2078759C (en) 1991-09-27 2003-09-16 Alan M. Warshawsky Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
JPH06107661A (ja) 1991-10-24 1994-04-19 Upjohn Co:The イミダゾール誘導体およびこれを有効成分とする医薬組成物
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US5977160A (en) * 1992-04-10 1999-11-02 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
JP3360079B2 (ja) * 1992-05-15 2002-12-24 メレルダウファーマスーティカルズ インコーポレイテッド エンケファリナーゼ及びＡＣＥの阻害剤として有用な新規なメルカプトアセチルアミドピリダゾ［１，２］ピリダジン、ピラゾロ［１，２］ピリダジン、ピリダゾ［１，２‐ａ］［１，２］ジアゼピン、及びピラゾロ［１，２‐ａ］［１，２］ジアゼピン誘導体類
EP0668864A1 (de) * 1992-07-17 1995-08-30 Merck & Co. Inc. Substituierte biphenylmethylimidazopyridine
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
GB9223860D0 (en) * 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
DE4308504A1 (de) 1993-03-18 1994-09-22 Knoll Ag Neue Verwendung einer Kombination aus Verapamil und Trandolapril
DE4309553A1 (de) * 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
WO1994028901A1 (fr) * 1993-06-11 1994-12-22 Eisai Co., Ltd. Derive aminoacide
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5362772A (en) * 1993-07-09 1994-11-08 E. I. Du Pont De Nemours And Company Crosslinked microgel for cathodic electrocoating compositions
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
ES2079315B1 (es) * 1994-02-24 1996-10-16 Uriach & Cia Sa J Nuevas imidazopiridinas.
ES2105939B1 (es) * 1994-08-02 1998-07-01 Uriach & Cia Sa J Nuevos pirazoles con actividad antagonista de la angiotensina ii.
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
EP0738510A3 (de) * 1995-04-20 2005-12-21 L'oreal Verwendung eines HMG-CoA-Reduktase Inhibitors als Hautalterungschutzmittel und als Anti-Aknemittel. Zusammensetzung enthaltend mindestens einen HMG-CoA-Reduktase Inhibitor und mindestens einen Wirkstoff mit abschuppenden Eigenschaften
US5656603A (en) * 1995-05-31 1997-08-12 Loyola University Of Chicago Aminopeptidase P inhibitors and uses thereof
EP0795327A1 (de) * 1996-03-13 1997-09-17 Pfizer Inc. Verwendung von Amlodipin zur Behandlung von Prophylaxe von kongestivem Herzversagen nichtischämischen Ursprungs
JPH1081633A (ja) * 1996-07-16 1998-03-31 Sankyo Co Ltd 医薬組成物
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
AU742506B2 (en) * 1997-10-17 2002-01-03 Eurogene Limited The use of inhibitors of the renin-angiotensin system
US6403856B1 (en) * 1998-10-19 2002-06-11 Uop Llc Process for separating alkylaromatic hydrocarbons
DE19913528A1 (de) 1998-12-21 2000-06-29 Sanol Arznei Schwarz Gmbh Neue Verwendung von Moexipril
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
HUP0203326A3 (en) * 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
CA2467095A1 (en) * 2001-11-23 2003-05-30 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident

Also Published As

Publication number Publication date
AU2005209687A1 (en) 2005-10-06
HUP0203326A3 (en) 2003-04-28
RU2276997C2 (ru) 2006-05-27
YU8502A (sh) 2004-12-31
SK2692002A3 (en) 2002-07-02
ZA200201470B (en) 2003-09-23
US7368469B2 (en) 2008-05-06
HK1048267B (zh) 2006-12-08
KR20020040795A (ko) 2002-05-30
NZ517468A (en) 2004-02-27
WO2001015674A2 (en) 2001-03-08
WO2001015674A3 (en) 2002-03-28
AU2009200746B2 (en) 2011-07-28
AU7649100A (en) 2001-03-26
RS50377B (sr) 2009-11-10
HUP0203326A2 (hu) 2003-02-28
EE200200086A (et) 2003-04-15
NO20020978L (no) 2002-04-18
UA88265C2 (ru) 2009-10-12
IL148127A0 (en) 2002-09-12
US20080287403A1 (en) 2008-11-20
EE05670B1 (et) 2013-08-15
CZ300687B6 (cs) 2009-07-15
CA2382549A1 (en) 2001-03-08
RU2005141759A (ru) 2007-07-10
HRP20020170A2 (en) 2005-10-31
CZ2002770A3 (cs) 2002-06-12
CN1268331C (zh) 2006-08-09
US20040087645A1 (en) 2004-05-06
JP2003527325A (ja) 2003-09-16
DK1216038T3 (da) 2005-12-27
US20050101658A1 (en) 2005-05-12
EP1216038B1 (de) 2005-09-07
ES2246894T3 (es) 2006-03-01
ATE303800T1 (de) 2005-09-15
MXPA02001694A (es) 2002-08-06
CN1368881A (zh) 2002-09-11
BR0013704A (pt) 2002-05-07
BG65474B1 (bg) 2008-09-30
JP4870888B2 (ja) 2012-02-08
US20070021491A1 (en) 2007-01-25
IL148127A (en) 2015-07-30
PL353199A1 (en) 2003-11-03
NO20020978D0 (no) 2002-02-27
BG110003A (bg) 2008-06-30
TR200200515T2 (tr) 2002-11-21
DE60022525D1 (de) 2005-10-13
EP1216038A2 (de) 2002-06-26
HK1048267A1 (en) 2003-03-28
ME00429B (me) 2011-10-10
KR20120055730A (ko) 2012-05-31
NO331616B1 (no) 2012-02-06
UA77151C2 (en) 2006-11-15
BG106360A (en) 2002-10-31
NZ530702A (en) 2005-07-29
CA2382549C (en) 2005-03-15
AU2009200746A1 (en) 2009-03-19
AU2009200746B8 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
DE60022525D1 (de) Ramipril zur vorbeugung von kardiovaskulären vorfällen
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
UA88270C2 (ru) Фармацевтический препарат и его применение для профилактики удара, диабета
PL349223A1 (en) Solid−state form of celecoxib having enhanced bioavailability
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2001041754A8 (en) Inhibitors of collagen-induced platelet aggregation
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
WO2002072104A3 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO1999056734A3 (de) Transdermales therapeutisches system zur anwendung von candesartan
WO2003101380A3 (en) Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
EP1611886A3 (de) Hemmer des Renin-Angiotensin-Systems zur Vorbeugung von kardiovaskulären Funktionsstörungen
ATE259229T1 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
NZ503559A (en) Compositions and methods for the control of smoking containing a xanthine oxidase inhibitor

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,

8363 Opposition against the patent